Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP

 Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP

Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

Shots:

  • The P-III RESTORE-IMI 2 study involves assessing of Recarbrio (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) vs Piperacillin/Tazobactam in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
  • The P-III RESTORE-IMI 2 study resulted in meeting its 1EPs & 2EPs of statistical non-inferiority           in Day 28 all-cause mortality and clinical response at early follow-up, respectively
  • Recarbio (IV) is a combination of penem antibacterial drug, renal dehydropeptidase inhibitor & beta-lactamase inhibitor, its component Relebactam has received FDA’s QIDP, Fast Track designation for HABP/VABP

Click here to­ read full press release/ article | Ref: Businesswire | Image: WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post